EFAVALEUKIN ALFA IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A BAYESIAN ADAPTIVE, PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED DOSE-RANGING STUDY

Authors
Category Primary study
JournalJ. Rheumatol.
Year 2025
This article has no abstract
Epistemonikos ID: 5e568861df1eeae4a8a514f86edb6ca03905531e
First added on: Jul 12, 2025